APA (7th ed.) Citation

Kunkel, J. B., Holle, S. L. D., Hassager, C., Pecini, R., Wiberg, S., Palm, P., . . . Søholm, H. (2024). Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T). Trials, 25(1), . https://doi.org/10.1186/s13063-024-08573-0

Chicago Style (17th ed.) Citation

Kunkel, Joakim Bo, et al. "Interleukin-6 Receptor Antibodies (tocilizumab) in Acute Myocardial Infarction with Intermediate to High Risk of Cardiogenic Shock Development (DOBERMANN-T)." Trials 25, no. 1 (2024). https://doi.org/10.1186/s13063-024-08573-0.

MLA (9th ed.) Citation

Kunkel, Joakim Bo, et al. "Interleukin-6 Receptor Antibodies (tocilizumab) in Acute Myocardial Infarction with Intermediate to High Risk of Cardiogenic Shock Development (DOBERMANN-T)." Trials, vol. 25, no. 1, 2024, https://doi.org/10.1186/s13063-024-08573-0.